Intellia Therapeutics (NTLA) Revenue (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Revenue data on file, last reported at $15.0 million in Q1 2026.

• Revenue for Q1 2026 came in at $15.0 million, down 9.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $66.1 million (up 45.04% YoY), and the FY2025 annual result was $67.7 million, up 16.92% from the prior year.
• Revenue declined to $15.0 million in Q1 2026 per NTLA's latest filing, from $23.0 million in the prior quarter.
• Over five years, Revenue peaked at $28.9 million in Q1 2024 and troughed at -$1.9 million in Q4 2023.
• A 5-year average of $13.5 million and a median of $13.6 million in 2022 frame the typical range for Revenue.
• The sharpest annual moves came in 2022 and 2023: Revenue surged 4322.0% in 2022, then plunged 114.12% in 2023.
• A 5-year view of Revenue shows it stood at $13.6 million in 2022, then sank by 114.12% to -$1.9 million in 2023, then surged by 771.57% to $12.9 million in 2024, then jumped by 78.79% to $23.0 million in 2025, then slumped by 34.62% to $15.0 million in 2026.
• Business Quant data shows NTLA's Revenue at $15.0 million in Q1 2026, $23.0 million in Q4 2025, and $13.8 million in Q3 2025.